Verona Pharma Announces Publication of Key Phase 2b ...
Ensifentrine, a novel inhaled dual phosphodiesterase 3 and 4 inhibitor, showed significant improvements in lung function and COPD symptoms in Phase 2b trials, offering potential as a first-in-class therapy combining bronchodilator and anti-inflammatory effects.
Reference News
Verona Pharma Announces Publication of Key Phase 2b ...
Ensifentrine, a novel inhaled dual phosphodiesterase 3 and 4 inhibitor, showed significant improvements in lung function and COPD symptoms in Phase 2b trials, offering potential as a first-in-class therapy combining bronchodilator and anti-inflammatory effects.